Sold as Halfan. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Halofantrine Hydrochloride (sold as Halfan), first approved Jul 24, 1992, with 0 new uses approved and 0 published complete response letters.
| RSV Vaccination to Reduce Recurrent AECOPDCOPD, RSV · Chinese University of Hong Kong | Phase 4 | Not yet recruiting | Apr 2, 2026 |
| Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)Influenza (Pandemic), Avian Influenza · University Health Network, Toronto | Phase 3 | Active, not recruiting | Nov 21, 2025 |
| A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy IndividualsHerpes Zoster (HZ) · Shanghai Institute Of Biological Products | Phase 1 / Phase 2 | Recruiting | Apr 17, 2025 |
| Reward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed PeopleMajor Depressive Disorder (MDD) · Medical University of Vienna | Phase 4 | Recruiting | Nov 5, 2024 |
| Dental Biofilm Control During Orthodontic TreatmentGingivitis, Malocclusion · University of Rijeka | Phase 3 | Active, not recruiting | Sep 8, 2022 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jul 24, 1992 | HalfanNDA 20250 · New molecular entity | Glaxosmithkline | 7 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA